Ofra Barnett-Griness
Ofra Barnett-Griness has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anat Arbel
Department of Internal Medicine B Lady Davis Carmel Medical Center Haifa Israel
2 shared publications - Ronza Najjar-Debbiny
Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Infection Prevention and Control Unit, Lady Davis Carmel Medical Center, Haifa, Israel
2 shared publications - Eitan Auriel
From the Department of Neurology (Y.W., M.F., J.N., R.B., E.A.), Rabin Medical Center, Petah Tikva, Israel and Department of Neurology (A.H.), Soroka Medical Center, Be'er Sheva, Israel.
1 shared publication Gabriel Weber
Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel
1 shared publication- Haya Bishara
Neurology Department, Carmel Medical Center, Haifa 3436212, Israel
1 shared publication Inbal Greenfeld
Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel
1 shared publication
Latest Publications
- 6 May 2024
- Published by Elsevier in Microbes and Infection
- Vol. 26 (5-6) , 105349
Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study
- 6 May 2024
- Published by Elsevier in Microbes and Infection
- Vol. 26 (5-6) , 105349
Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study
- 14 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (20) , E2035-E2042
Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination
Background and Objectives: Existing data regarding occurrence of Guillain-Barré syndrome (GBS) following COVID-19 infection and vaccination are inconclusive. We aimed to assess the association between GBS and both SARS-CoV-2 infection and COVID-19 vaccine. Methods: We conducted a nested-case control study in a cohort of 3,193,951 patients aged≥16 years, without a diagnosis of prior GBS, from the largest healthcare provider in Israel. Subjects were followed from January 1st, 2021, until June 30th, 2022, for the occurrence of GBS. Ten randomly selected controls were matched to each case of GBS on age and sex. We assessed both SARS-CoV-2 infection and COVID-19 vaccine administration in the prior 6 weeks in cases and controls. Results: Overall, 76 patients were diagnosed with GBS during follow-up and were matched to 760 controls. A positive test for SARS-CoV-2 was detected in 9 (11.8%) cases, and 18 (2.4%) controls. An administration of COVID-19 vaccine was detected in 8 (10.5%) cases (all Pfizer-BioNTech [BNT162b2] vaccine), and 136 (17.9%) controls (134 Pfizer-BioNTech vaccine). Multivariable conditional logistic regression models showed that the OR for GBS associated with SARS-CoV-2 infection and COVID-19 vaccine administration was 6.30 (95% CI 2.55-15.56) and 0.41 (95% CI 0.17-0.96), respectively. The results were similar when exposure to SARS-CoV-2 infection or COVID-19 vaccine administration were ascertained in the prior 4 and 8 weeks, although did not reach statistical significance for COVID-19 vaccine at 4 weeks. Conclusions: Our study suggests that SARS-CoV-2 infection is associated with increased risk of GBS, while Pfizer-BioNTech COVID-19 vaccine is associated with decreased risk of GBS.
- 14 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (20) , E2035-E2042
Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination
Background and Objectives: Existing data regarding occurrence of Guillain-Barré syndrome (GBS) following COVID-19 infection and vaccination are inconclusive. We aimed to assess the association between GBS and both SARS-CoV-2 infection and COVID-19 vaccine. Methods: We conducted a nested-case control study in a cohort of 3,193,951 patients aged≥16 years, without a diagnosis of prior GBS, from the largest healthcare provider in Israel. Subjects were followed from January 1st, 2021, until June 30th, 2022, for the occurrence of GBS. Ten randomly selected controls were matched to each case of GBS on age and sex. We assessed both SARS-CoV-2 infection and COVID-19 vaccine administration in the prior 6 weeks in cases and controls. Results: Overall, 76 patients were diagnosed with GBS during follow-up and were matched to 760 controls. A positive test for SARS-CoV-2 was detected in 9 (11.8%) cases, and 18 (2.4%) controls. An administration of COVID-19 vaccine was detected in 8 (10.5%) cases (all Pfizer-BioNTech [BNT162b2] vaccine), and 136 (17.9%) controls (134 Pfizer-BioNTech vaccine). Multivariable conditional logistic regression models showed that the OR for GBS associated with SARS-CoV-2 infection and COVID-19 vaccine administration was 6.30 (95% CI 2.55-15.56) and 0.41 (95% CI 0.17-0.96), respectively. The results were similar when exposure to SARS-CoV-2 infection or COVID-19 vaccine administration were ascertained in the prior 4 and 8 weeks, although did not reach statistical significance for COVID-19 vaccine at 4 weeks. Conclusions: Our study suggests that SARS-CoV-2 infection is associated with increased risk of GBS, while Pfizer-BioNTech COVID-19 vaccine is associated with decreased risk of GBS.